Clinical trials: Adherence
Bipolar 1 Disorder, Schizophrenia
Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia
The purpose of this study is to evaluate the pharmacokinetics of aripiprazole in subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal aderence and are currently on treatment with oral aripiprazole.
- Conditions
- Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Disorders
- Trial name
- NCT02050854
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Human Immunodeficiency Virus Infection
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
Both twice-a-day (BID) and once-a-day (QD) dosing are approved in Europe for the protease inhibitor lopinavir/ritonavir (LPV/r; Kaletra®).
- Trial name
- QD-Kapital (NCT01383005)
- Where
- 20 sites in Spain
- Volunteers
- 97 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Multiple Sclerosis
Therapy Optimization in Multiple Sclerosis (MS)
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
- Trial name
- TOP MS (NCT00819000)
- Testing
- Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
- Where
- 3 sites in United States
- Volunteers
- 2,878 people
- Sponsor
- Teva Neuroscience, Inc.
Bipolar Disorders
Study of the Clinical Management of Bipolar Disease
This study is to provide reliable information on the management of bipolar disorders in real every day, clinical practice, to determine the clinical outcomes of such management and use of resources in relation to the disease, and…
- Trial name
- WAVE bd (NCT01062607)
- Where
- 213 sites in Austria, Belgium and 8 more
- Volunteers
- 2,965 people
- Sponsor
- AstraZeneca
Medication Adherence, Hypertension
An Enhanced Medication Monitoring Program
The goal of the Enhanced Medication Management Program (eMMp) being developed by MedMinder Systems, Inc. is to increase the ability of frail elders to adhere to complex medication regimens for chronic conditions.
- Trial name
- NCT01105104
- Testing
- MedMinder System, MedMinder System - deactivated
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- MedMinder Systems Inc.
Hypertension
To Assess Adherence to the Treatment and Quality of Life in Patients With Hypertension
The main goal of this study is to achieve a deeper knowledge of the adherence to antihypertensive drug treatment and to evaluate the quality of life in this population.
- Trial name
- ADHERENCE (NCT00944489)
- Where
- Argentina
- Volunteers
- 1,150 people
- Sponsor
- AstraZeneca
Schizophrenia
Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia
This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.
- Trial name
- SMS (NCT00873249)
- Where
- 25 sites in Spain
- Volunteers
- 339 people
- Sponsor
- AstraZeneca